Process
AssigneeSun Pharmaceutical Industries (Australia) Pty Ltd
InventorsXu Li, Sally Louise Gras, Garrick Westley Kyle Spencer
Life of this patent
Estimating the term…
Abstract
The disclosure relates to a biotransformation for the manufacture of one or more opiate or opioid alkaloids using a crude poppy extract or a purified or semi-purified source of opiate or opioid alkaloid; vectors comprising nucleic acid molecules encoding enzymes; microbial cells expressing nucleic acids encoding said enzymes and including modified enzymes with enhanced activity.
Claims35
A method for the biotransformation of one or more opiate alkaloids or synthetic opioid alkaloids or derivatives thereof comprising the steps:
- forming a preparation comprising a host cell transformed with one or more nucleic acid molecules encoding one or more polypeptides capable of catalysing at least one reaction in the conversion of one or more opiate alkaloids or synthetic opioid alkaloids or derivatives thereof to one or more different opiate alkaloids or semi-synthetic opioid alkaloids or derivatives thereof,
- incubating the reaction to allow transformation of one or more opiate alkaloids or semi-synthetic opioid alkaloids or derivatives thereof;
- and optionally
- extracting said one or more transformed different opiate alkaloids or semi-synthetic opioid alkaloids or derivatives thereof from said preparation.
4-17. (canceled)
21-22. (canceled)
26-27. (canceled)
A modified codeine 3-O-demethylase polypeptide wherein the activity of said modified codeine 3-O-demethylase polypeptide is altered when compared to a non-modified codeine 3-O-demethylase.
31-33. (canceled)
35-36. (canceled)
38-43. (canceled)
(canceled)
51-56. (canceled)
63-74. (canceled)
Dependencies are inferred from the claim text.